Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cordlife Group Limited (P8A.SI)
Singapore, SG
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its operations are structured into two distinct divisions: Banking and Diagnostics. The Banking division is responsible for the collection, processing, storage, and analysis of vital biological samples such as cord blood, cord lining, and various tissue samples. Meanwhile, the Diagnostics division furnishes an array of diagnostic tests, encompassing genetic and metabolic screenings for newborns, pediatric vision and hearing assessments, allergen testing for children, and genetic evaluations for talent identification. Beyond these core services, Cordlife also engages in corneal lenticule banking, gut microbiome storage, and offers lifestyle-focused genetic screening for adults. The company further provides "Moms Up," a mobile application designed to supply parenting information and resources pertinent to health, wellness, and lifestyle needs. Completing its diverse portfolio, Cordlife offers medical laboratory services, marketing support, property investment, alongside specialized consulting and research and development in the medical and pharmaceutical sectors.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -19.87% | -18.79% | -24.38% | -6.92% | -54.34% | -66.39% | -66.39% | -90.97% | -83.31% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%-50.0% Q2'25: +122.6% (vs Q2'24)
-
EPS growth Medical - Diagnostics & Research: +30.8%-638.0% Q2'25: +60.1% (vs Q2'24)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-45.5% Q2'25: -13.1% (vs Q2'24)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-66.8% Q2'25: -32.7% (vs Q2'24)
-
ROIC Medical - Diagnostics & Research: +5.2%-30.8% Q2'25: -16.2% (vs Q2'24)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.0% ★ Q2'25: +0.0% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.17× Q2'25: -0.17× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xiaoling Chen | Group Chief Executive Officer, Executive Director & CEO of Singapore | 408.0K | female |
| Hui Yee Cheok | Joint Company Secretary | — | female |
| Janice Ong | Country Chief Executive Officer of Cordlife Singapore | — | female |
| Lucy Lai | Country Chief Executive Officer of Healthbaby Hong Kong- Cordlife Hong Kong | — | female |
| Michael Arnonobal | Country Chief Executive Officer of Cordlife Philippines | — | male |
| Raymond Wong | Country Chief Executive Officer of Stemlife Malaysia | — | male |
| Retno Suprihatin | Country Chief Executive Officer of Cordlife Idonesia | — | female |
| Upamannyue Chowdhury | Country Chief Executive Officer of Cordlife India | — | male |
| Xun Er Goh | Joint Company Secretary | — | female |
| Hnin Yi Thet | Executive Officer | — | female |
| Yifei Wu | Group Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for P8A.SI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
